Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/8/2020
SIETES contiene 93083 citas

 
 
 1 a 20 de 238 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817-25. [Ref.ID 93639]
3.Tiene citas relacionadas
Stone GW, Mehran R. Bivalirudin for patients with ST-elevation myocardial infarction. Authors' reply. Lancet 2011;378:1915-6. [Ref.ID 91912]
4.Tiene citas relacionadas
Dwivedi G, Steed R, Chong AY. Bivalirudin for patients with ST-elevation myocardial infarction. Lancet 2011;378:1915. [Ref.ID 91911]
5. Cita con resumen
Kastrati A, Neumann F-J, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz K-L, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schömig A, Berger PB, Mehilli J, for the ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011;365:1980-9. [Ref.ID 91609]
6.Enlace a cita original
Anónimo. NICE Guidance - October 2011. Prescribing Advice for GPs 2011:octubre. [Ref.ID 91579]
7.
Anónimo. Ticagrelor (Brilinta) - Better than clopidogrel (Plavix)?. Med Lett Drugs Ther 2011;53:69-70. [Ref.ID 91447]
8.Tiene citas relacionadas
Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R, on behalf of the HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204. [Ref.ID 91347]
9.Tiene citas relacionadas
Mukherjee D. Antithrombotics and stent type for primary PCI. Lancet 2011;377:2154-6. [Ref.ID 91343]
10.Tiene citas relacionadas Cita con resumen
Bousser M-G, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci M-D, on behalf of the PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011;377:2013-22. [Ref.ID 91303]
11.Tiene citas relacionadas Cita con resumen
Lee M, Ovbiagele B. Vascular events after stroke: terutroban fails to PERFORM. Lancet 2011;377:1980-2. [Ref.ID 91298]
12. Cita con resumen
Anónimo. Ticagrelor for acute coronary syndrome?. Drug Ther Bull 2011;49:66-8. [Ref.ID 91221]
13.
14.
James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA, for the PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO. BMJ 2011;342:1403. [Ref.ID 90953]
15.Tiene citas relacionadas Cita con resumen
Stone GW. Ticagrelor in ACS: redefining a new standard of care?. Lancet 2010;375:263-5. [Ref.ID 87548]
16.Tiene citas relacionadas Cita con resumen
Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L, for the PLATelet inhibition and patient Outcomes (PLATO) investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93. [Ref.ID 87547]
17.Tiene citas relacionadas Cita con resumen
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikoslky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, for the HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-59. [Ref.ID 86874]
18.Tiene citas relacionadas Cita con resumen
Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374:787-95. [Ref.ID 86737]
19.Tiene citas relacionadas
Eikelboom JW, Weitz JI. Otamixaban in acute coronary syndromes. Lancet 2009;374:762-4. [Ref.ID 86735]
20. Cita con resumen
Schömig A. Ticagrelor-Is there need for a new player in the antiplatelet-therapy field?. N Engl J Med 2009;361:1108-11. [Ref.ID 86475]
Seleccionar todas
 
 1 a 20 de 238 siguiente >>